Ganitumab (currently in a metastatic Ewing sarcoma clinical trial) and mammalian target of rapamycin (mTOR) inhibitors (currently in a trial proposal) are also included using the task force’s work flow for comparison. Here, MTOR is linked to Ewing sarcoma.